Blackstone Invests $400 Million in Teva's Autoimmune Disease Drug Development
Blackstone has committed $400 million to fund the development of Teva's autoimmune disease drug duvakitug, signaling confidence in Teva's future. The investment highlights Blackstone's expertise in healthcare and its high success rate in commercializing drugs. This move may indicate a broader turnaround for Teva.
Topics: Blackstone drug development investment pharmaceuticals Teva